Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
The New England Journal of Medicine
|
January 16, 2009
Hepatitis B virus infection
Juan Miguel Bergua, Carmen Cabrera, Helena Bañas
Leukemia Research
|
January 18, 2014
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile
Steven Knapper, Timothy Chevassut, Rafael Duarte, et al.
Blood
|
June 27, 2023
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, et al.
Blood Advances
|
February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Jason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Future Oncology (London, England)
|
June 19, 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
Blood
|
July 10, 2008
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosiñol, José Antonio Pérez-Simón, Anna Sureda, et al.
Frontiers in Oncology
|
December 12, 2022
The transcriptomic landscape of elderly acute myeloid leukemia identifies <i>B7H3</i> and <i>BANP</i> as a favorable signature in high-risk patients
Sara Villar, Beñat Ariceta, Xabier Agirre, et al.
Annals of Hematology
|
April 29, 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
María P Martínez Sánchez, Juan Eduardo Megías-Vericat, Rebeca Rodríguez-Veiga, et al.
European Journal of Haematology
|
April 4, 2020
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
Marta Sitges, Blanca Boluda, Ana Garrido, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
The New England Journal of Medicine
|
January 16, 2009
Hepatitis B virus infection
Juan Miguel Bergua, Carmen Cabrera, Helena Bañas
Leukemia Research
|
January 18, 2014
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile
Steven Knapper, Timothy Chevassut, Rafael Duarte, et al.
Blood
|
June 27, 2023
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, et al.
Blood Advances
|
February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Jason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Future Oncology (London, England)
|
June 19, 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
Blood
|
July 10, 2008
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosiñol, José Antonio Pérez-Simón, Anna Sureda, et al.
Frontiers in Oncology
|
December 12, 2022
The transcriptomic landscape of elderly acute myeloid leukemia identifies <i>B7H3</i> and <i>BANP</i> as a favorable signature in high-risk patients
Sara Villar, Beñat Ariceta, Xabier Agirre, et al.
Annals of Hematology
|
April 29, 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
María P Martínez Sánchez, Juan Eduardo Megías-Vericat, Rebeca Rodríguez-Veiga, et al.
European Journal of Haematology
|
April 4, 2020
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
Marta Sitges, Blanca Boluda, Ana Garrido, et al.
Page
of 5